{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-146581","form_type":"8-K","ticker":"HRGN","cik":"0001563665","company_name":"Harvard Apparatus Regenerative Technology, Inc.","filed_at":"2021-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.050015+00:00","generated_at":"2026-06-28T03:30:51.450066+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biostage highlights first-in-human esophageal success, FDA-approved IND, founder CEO return","bullets":["First-in-human esophageal implant at Mayo Clinic; paper published Aug 2021 concludes 'considerable clinical use'.","FDA-approved IND for Phase 1/2 trial (10 patients); two orphan-drug designations provide 7-year exclusivity.","Founder David Green returned as interim CEO and Chairman in Nov 2021; invested $250k in BSTG; compensation in options.","Cash ~$1.7M as of Nov 30, 2021; burn ~$250k/month; goals include raising capital, commencing trial, NASDAQ uplist."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-146581","json":"https://secwatch.observer/filing/0001104659-21-146581.json","markdown":"https://secwatch.observer/filing/0001104659-21-146581.md","text":"https://secwatch.observer/filing/0001104659-21-146581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563665/000110465921146581/0001104659-21-146581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563665/000110465921146581/tm2134645d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:30:51.450066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}